229 related articles for article (PubMed ID: 7686113)
1. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.
Tassopoulos NC; Koutelou MG; Papatheodoridis G; Polychronaki H; Delladetsima I; Giannikakis T; Todoulos A; Toliopoulos A; Hatzakis A
Gut; 1993; 34(2 Suppl):S130-2. PubMed ID: 7686113
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interferon alfa-2b treatment in chronic non-A, non-B/type C hepatitis.
De Conca V; Mesiti S; Vallarino E; Mornese A; Dodero M
Gut; 1993; 34(2 Suppl):S126. PubMed ID: 8314477
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b.
Genesca J; Esteban JI; Quer J; Viladomiu LL; Gonzalez A; Esteban R; Guardia J
Gut; 1993; 34(2 Suppl):S62-3. PubMed ID: 7686120
[TBL] [Abstract][Full Text] [Related]
4. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
Lampertico P; Rumi M; Romeo R; Craxì A; Soffredini R; Biassoni D; Colombo M
Hepatology; 1994 Jan; 19(1):19-22. PubMed ID: 7506225
[TBL] [Abstract][Full Text] [Related]
5. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis.
Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F
J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007
[TBL] [Abstract][Full Text] [Related]
6. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B.
Hadziyannis S; Bramou T; Makris A; Moussoulis G; Zignego L; Papaioannou C
J Hepatol; 1990; 11 Suppl 1():S133-6. PubMed ID: 2079571
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa for chronic hepatitis C in haemophiliacs.
Makris M; Preston FE; Triger DR; Underwood JC; Westlake L; Adelman MI
Gut; 1993; 34(2 Suppl):S121-3. PubMed ID: 8314476
[TBL] [Abstract][Full Text] [Related]
8. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.
Poynard T; Bedossa P; Chevallier M; Mathurin P; Lemonnier C; Trepo C; Couzigou P; Payen JL; Sajus M; Costa JM
N Engl J Med; 1995 Jun; 332(22):1457-62. PubMed ID: 7739681
[TBL] [Abstract][Full Text] [Related]
9. Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion.
Colombo M; Lampertico P; Rumi M
Gut; 1993; 34(2 Suppl):S141. PubMed ID: 8314483
[TBL] [Abstract][Full Text] [Related]
10. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis.
Di Bisceglie AM; Martin P; Kassianides C; Lisker-Melman M; Goodman Z; Banks SM; Hoofnagle JH
J Hepatol; 1990; 11 Suppl 1():S36-42. PubMed ID: 2127786
[TBL] [Abstract][Full Text] [Related]
12. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
[TBL] [Abstract][Full Text] [Related]
13. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.
Reichard O; Glaumann H; Norkrans G; Wejstål R; Fryden A; Schvarcz R; Weiland O
Liver; 1994 Aug; 14(4):169-74. PubMed ID: 7526108
[TBL] [Abstract][Full Text] [Related]
14. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience.
Weiland O; Schvarcz R; Wejstål R; Norkrans G; Frydén A
J Hepatol; 1990; 11 Suppl 1():S57-62. PubMed ID: 2127789
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.
Saracco G; Rosina F; Torrani Cerenzia MR; Lattore V; Chiandussi L; Gallo V; Petrino R; De Micheli AG; Donegani E; Solinas A
J Hepatol; 1990; 11 Suppl 1():S43-9. PubMed ID: 2127787
[TBL] [Abstract][Full Text] [Related]
16. Mooren-type hepatitis C virus-associated corneal ulceration.
Wilson SE; Lee WM; Murakami C; Weng J; Moninger GA
Ophthalmology; 1994 Apr; 101(4):736-45. PubMed ID: 7512254
[TBL] [Abstract][Full Text] [Related]
17. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histological evaluation of interferon alfa-2b in the treatment of chronic hepatitis C.
Panella C; Francavilla A; Conte D; Tatulli I; Rubini F
Gut; 1993; 34(2 Suppl):S127. PubMed ID: 8314478
[TBL] [Abstract][Full Text] [Related]
19. Interferon therapy for non-A, non-B hepatitis: a pilot study and review of the literature.
Yamamoto H; Hayashi E; Nakamura H; Kimura Y; Ito H; Kambe H
Hepatogastroenterology; 1992 Oct; 39(5):377-80. PubMed ID: 1334037
[TBL] [Abstract][Full Text] [Related]
20. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.
Marcellin P; Pouteau M; Martinot-Peignoux M; Degos F; Duchatelle V; Boyer N; Lemonnier C; Degott C; Erlinger S; Benhamou JP
Gastroenterology; 1995 Jul; 109(1):156-65. PubMed ID: 7540996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
